JP2019537619A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019537619A5 JP2019537619A5 JP2019538088A JP2019538088A JP2019537619A5 JP 2019537619 A5 JP2019537619 A5 JP 2019537619A5 JP 2019538088 A JP2019538088 A JP 2019538088A JP 2019538088 A JP2019538088 A JP 2019538088A JP 2019537619 A5 JP2019537619 A5 JP 2019537619A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- patient
- composition according
- antibody
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 31
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 14
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 14
- 239000008280 blood Substances 0.000 claims 12
- 210000004369 blood Anatomy 0.000 claims 12
- 229960002621 pembrolizumab Drugs 0.000 claims 12
- 238000002965 ELISA Methods 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 5
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 5
- 229950007843 bavituximab Drugs 0.000 claims 4
- 230000003442 weekly effect Effects 0.000 claims 4
- 102100030802 Beta-2-glycoprotein 1 Human genes 0.000 claims 2
- 101710180007 Beta-2-glycoprotein 1 Proteins 0.000 claims 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 238000006424 Flood reaction Methods 0.000 claims 1
- 206010062878 Gastrooesophageal cancer Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000006974 gastroesophageal cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000029824 high grade glioma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000011614 malignant glioma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662400589P | 2016-09-27 | 2016-09-27 | |
| US62/400,589 | 2016-09-27 | ||
| US201662406727P | 2016-10-11 | 2016-10-11 | |
| US62/406,727 | 2016-10-11 | ||
| US201762480994P | 2017-04-03 | 2017-04-03 | |
| US62/480,994 | 2017-04-03 | ||
| US201762507580P | 2017-05-17 | 2017-05-17 | |
| US62/507,580 | 2017-05-17 | ||
| PCT/US2017/053370 WO2018064013A1 (en) | 2016-09-27 | 2017-09-26 | METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019537619A JP2019537619A (ja) | 2019-12-26 |
| JP2019537619A5 true JP2019537619A5 (enExample) | 2020-11-12 |
Family
ID=66538296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538088A Pending JP2019537619A (ja) | 2016-09-27 | 2017-09-26 | β２−糖タンパク質１のレベルに基づいて、バビツキシマブで癌を治療するための方法、およびそのためのアッセイ |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3519827A1 (enExample) |
| JP (1) | JP2019537619A (enExample) |
| KR (1) | KR20190057303A (enExample) |
| CN (1) | CN109863402A (enExample) |
| AU (1) | AU2017334698A1 (enExample) |
| CA (1) | CA3037008A1 (enExample) |
| MX (1) | MX2019003569A (enExample) |
| WO (1) | WO2018064013A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018187227A1 (en) * | 2017-04-03 | 2018-10-11 | Concologie, Inc. | Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents |
| EP3837546A1 (en) * | 2018-08-13 | 2021-06-23 | Regeneron Pharmaceuticals, Inc. | Therapeutic protein selection in simulated in vivo conditions |
| EP4021940A1 (en) * | 2020-05-12 | 2022-07-06 | Astrazeneca AB | Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies |
| CN112698033A (zh) * | 2020-12-09 | 2021-04-23 | 复旦大学附属中山医院 | 一种血源性外泌体her2的检测方法及其应用 |
| CN114716547B (zh) * | 2022-05-18 | 2023-11-21 | 珠海丽禾医疗诊断产品有限公司 | 一种包括抗原结合结构域的结合蛋白及其生产方法和应用 |
| WO2024065243A1 (en) * | 2022-09-28 | 2024-04-04 | University Of Macau | Drug for treatment of breast cancer and application thereof |
| CN119555937B (zh) * | 2025-01-26 | 2025-05-20 | 杭州奥泰生物技术股份有限公司 | 一种犬虫媒病五联抗体检测卡及其制备方法和试剂盒 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5019368A (en) | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
| WO1998042752A1 (en) | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Immunotherapeutic ctla-4 binding peptides |
| US6406693B1 (en) | 1998-07-13 | 2002-06-18 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
| US6818213B1 (en) | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
| BR9911882A (pt) | 1998-07-13 | 2005-02-15 | Univ Texas | Processo de tratamento de câncer empregando anticorpos a aminofosfolipìdios |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| US7906115B2 (en) | 2002-07-15 | 2011-03-15 | Thorpe Philip E | Combinations kits and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| AU2012201537B2 (en) * | 2002-07-15 | 2014-06-05 | Board Of Regents, The University Of Texas System | Peptides binding to phosphatidylethanolamine and their use in treating viral infections and cancer |
| US7247303B2 (en) | 2002-07-15 | 2007-07-24 | Board Of Regents, The University Of Texas System | Selected antibody CDRs for binding to aminophospholipids |
| US7455833B2 (en) | 2002-07-15 | 2008-11-25 | Board Of Regents, The University Of Texas System | Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| US7611704B2 (en) | 2002-07-15 | 2009-11-03 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| US7572448B2 (en) | 2002-07-15 | 2009-08-11 | Board Of Regents, The University Of Texas System | Combined cancer treatment methods using selected antibodies to aminophospholipids |
| DK1853631T3 (en) | 2005-01-24 | 2016-03-29 | Univ Texas | Fc-FUSION CONSTRUCTIONS BINDING TO PHOSPHATIDYLSERINE AND THERAPEUTIC APPLICATION THEREOF |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| BRPI0820298A8 (pt) | 2007-11-09 | 2018-05-08 | Affitech Res As | composições e métodos de anticorpos anti-vegf |
| WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| NZ599405A (en) | 2009-11-24 | 2014-09-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| CA2940823C (en) | 2014-02-27 | 2017-03-28 | Board Of Regents, The University Of Texas System | Methods and compositions for isolating exosomes |
| EP3309174B1 (en) | 2014-07-11 | 2022-05-11 | Ventana Medical Systems, Inc. | Anti-pd-l1 antibodies and diagnostic uses thereof |
-
2017
- 2017-09-26 CN CN201780058161.8A patent/CN109863402A/zh active Pending
- 2017-09-26 MX MX2019003569A patent/MX2019003569A/es unknown
- 2017-09-26 WO PCT/US2017/053370 patent/WO2018064013A1/en not_active Ceased
- 2017-09-26 JP JP2019538088A patent/JP2019537619A/ja active Pending
- 2017-09-26 CA CA3037008A patent/CA3037008A1/en not_active Abandoned
- 2017-09-26 EP EP17791768.9A patent/EP3519827A1/en not_active Withdrawn
- 2017-09-26 KR KR1020197008828A patent/KR20190057303A/ko not_active Ceased
- 2017-09-26 AU AU2017334698A patent/AU2017334698A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019537619A5 (enExample) | ||
| Wu et al. | Astragalus polysaccharide enhanced antitumor effects of Apatinib in gastric cancer AGS cells by inhibiting AKT signalling pathway | |
| Otvos Jr et al. | Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer | |
| Wu et al. | Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF (V600E) mutant cancer cells | |
| ES2734673T3 (es) | Predicción de la sensibilidad farmacológica de tumores de pulmón basándose en identificaciones moleculares y genéticas | |
| Nikolaou et al. | The role of neurotensin and its receptors in non-gastrointestinal cancers: A review | |
| Mittal et al. | Recent advances in targeted therapy for glioblastoma | |
| Ferté et al. | IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy | |
| Ma et al. | NOD1 inhibits proliferation and enhances response to chemotherapy via suppressing SRC-MAPK pathway in hepatocellular carcinoma | |
| AU2018287519A1 (en) | Il-1beta binding antibodies for use in treating cancer | |
| JP6381735B2 (ja) | 併用抗がん剤の感受性判定マーカー | |
| Molife et al. | A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors | |
| Sasaki et al. | A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors | |
| Zhang et al. | Angiotensin-converting enzyme inhibitors have adverse effects in anti-angiogenesis therapy for hepatocellular carcinoma | |
| Dittrich et al. | A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors | |
| Toi et al. | A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance | |
| JP2023156343A (ja) | がん幹細胞の低減におけるｗｎｔ５ａペプチド | |
| WO2019093383A1 (ja) | 抗ｐｄ－１抗体若しくは抗ｐｄ－ｌ１抗体療法の奏効性を予測する方法、がんの悪性度を評価する方法、及び抗ｐｄ－１抗体若しくは抗ｐｄ－ｌ１抗体療法の奏効性を上昇させる方法 | |
| CN117425515A (zh) | 用交变电场和曲妥珠单抗的组合进行治疗的组合物和方法 | |
| JP2017535548A5 (enExample) | ||
| Yuan et al. | Domperidone inhibits cell proliferation via targeting MEK and CDK4 in esophageal squamous cell carcinoma | |
| WO2018235056A1 (en) | Il-1beta binding antibodies for use in treating cancer | |
| Deneka et al. | Tumor-targeted SN38 inhibits growth of early stage non-small cell lung cancer (NSCLC) in a KRas/p53 transgenic mouse model | |
| Huhtala et al. | Biodistribution and antitumor effect of Cetuximab-targeted lentivirus | |
| US10933117B2 (en) | Endoplasmic reticulum stress as a predictive tool in cancer therapy and a combination therapy for the treatment of cancer |